Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Serratia Clinical Presentation

  • Author: Basilio J Anía, MD; Chief Editor: Michael Stuart Bronze, MD  more...
 
Updated: Oct 21, 2015
 

History

Sepsis

Patients with Serratia sepsis may present with fever, chills, shock, and respiratory distress.

Urinary tract infection

Approximately 30-50% of patients with Serratia urinary tract infections are asymptomatic. Symptoms may include fever, frequent urination, dysuria, pyuria, or pain upon urination.

In 90% of cases, patients have a history of recent surgery or instrumentation of the urinary tract.

Important risk factors for with Serratia urinary tract infections include diabetes mellitus, urinary tract obstruction, and renal failure.

Respiratory tract infection

Patients with Serratia respiratory tract infection are usually are colonized with Serratia species after instrumentation (eg, ventilation, bronchoscopy), especially those with chronic obstructive pulmonary disease.

Serratiapneumonia may develop, but this is rare. Patients with pneumonia may have fever, chills, productive cough (sometimes with pseudohemoptysis[21, 22] ), hypotension, dyspnea, and/or chest pain.

Meningitis or cerebral abscess

Serratia meningitis or cerebral abscesses may develop in premature children and neonates with prior sepsis. Patients who have experienced head trauma or have undergone neurosurgery,[23] lumbar puncture, or even epidural injections are at risk of developing meningitis or cerebral abscess.

The symptoms are those of gram-negative meningitis (eg, headache, fever, vomiting, stupor, coma).

Intra-abdominal infections

Patients with Serratia intra-abdominal infections may present with biliary drainage, hepatic abscess, pancreatic abscess, and peritoneal exudate. Serratia peritonitis can complicate peritoneal dialysis.[24]

Osteomyelitis and arthritis

Serratia osteomyelitis and arthritis may develop following hematogenous spread in persons who are addicted to intravenous drugs or may be caused exogenously by surgery, open trauma, or intra-articular injection. S marcescens osteomyelitis is a common presentation of chronic granulomatous disease in infancy.[25]

Endocarditis

Patients with Serratia endocarditis may present with fever, petechiae, and, occasionally, embolic complications (eg, stroke, arterial emboli).

Ocular infections

Patients with Serratia ocular infections present with keratitis or endophthalmitis.

Soft-tissue infections

Patients with Serratia soft-tissue infections may have surgical scars, cellulitis, phlebitis, or skin infections.

Otitis media

Patients with Serratiaotitis media present with earaches, hearing loss, and ear discharge.

Parotitis

Serratiaparotitis is rare.

Next

Physical

Pink hypopyon in the absence of hyphema may suggest S marcescens endophthalmitis.[26]

Breast milk can turn pink with Serratia postpartum mastitis.[27, 28]

Previous
Next

Causes

Sepsis or bacteremia

The main risk factor for Serratia sepsis/bacteremia is hospitalization. Placement of intravenous, intraperitoneal, or urinary catheters and prior instrumentation of the respiratory tract have been identified as risk factors among inpatients.

Other risk factors include cardiac valve replacement, transfusions, and the use of contaminated intravenous infusions. An outbreak of bacteremia was caused by pooling the residual contents of preservative-free epoetin vials for later use. Another outbreak was traced to tampering with an infused narcotic by a hospital employee.[29] A multistate outbreak of S marcescens bloodstream infection was linked to contaminated intravenous magnesium sulfate distributed in the United States by a compounding pharmacy.[30]

Contamination of a faucet resulted in 2 cases of bacteremia during an outbreak of 10 S marcescens infections in an intensive care unit.[31]

Urinary tract infection

Ninety percent of patients with Serratia urinary tract infection have a history of recent surgery or instrumentation of the urinary tract.

Important risk factors include diabetes mellitus, urinary tract obstruction, and renal failure.

Respiratory tract infection

Serratia respiratory tract infection may develop after instrumentation (eg, ventilation, bronchoscopy), especially in patients with chronic obstructive pulmonary disease. During an outbreak of S marcescens infections traced to a contaminated faucet (including consumption of tap water from the faucet) in an intensive care unit, 9 patients developed respiratory tract infection (8 developed septic bronchitis; 1 developed empyema), while another 9 patients developed only S marcescens colonization of the respiratory tract.[31]

Meningitis and cerebral abscess

Serratia meningitis or cerebral abscess may develop in premature children and neonates with prior sepsis. Serratia meningitis may also develop in adults who have experienced head trauma or have undergone neurosurgery, epidural injection, or lumbar puncture.

Osteomyelitis and arthritis

Osteomyelitis or arthritis can be hematogenous in people addicted to intravenous drugs, or can be caused exogenously by surgery, open trauma, or intraarticular injection.

Endocarditis

Although Serratia endocarditis tends to appear in intravenous drug abusers, it usually involves aortic or mitral valves.[32]

Ocular infections

Serratia infection frequently causes nonulcerating bacterial keratitis, which is associated with wearing rigid or soft contact lenses.[33]

Serratia endophthalmitis usually occurs after eye surgery.

Parotitis

Bacterial parotitis may develop in individuals with prior sialectasia.

Cutaneous infections

Poorly healing skin ulcers in combination with S marcescens infections at multiple sites are typical in young adults with chronic granulomatous disease.[25] Dermal abscesses and skin ulcers in the legs have appeared after a toe-web infection.[34]

Previous
 
 
Contributor Information and Disclosures
Author

Basilio J Anía, MD Associate Professor of Infectious Diseases, Universidad de Las Palmas de Gran Canaria; Consultant in Internal Medicine, Hospital Universitario Dr. Negrín, Spain

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

John L Brusch, MD, FACP Assistant Professor of Medicine, Harvard Medical School; Consulting Staff, Department of Medicine and Infectious Disease Service, Cambridge Health Alliance

John L Brusch, MD, FACP is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, Oklahoma State Medical Association, Southern Society for Clinical Investigation, Association of Professors of Medicine, American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Additional Contributors

Thomas E Herchline, MD Professor of Medicine, Wright State University, Boonshoft School of Medicine; Medical Director, Public Health, Dayton and Montgomery County, Ohio

Thomas E Herchline, MD is a member of the following medical societies: Alpha Omega Alpha, Infectious Diseases Society of Ohio, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

References
  1. Donnenberg MS. Enterobacteriaceae. Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th. Philadelphia, Pa: Churchill Livingstone - Elsevier; 2010. Vol 2: 2815-2833.

  2. Mahlen SD. Serratia infections: from military experiments to current practice. Clin Microbiol Rev. 2011 Oct. 24(4):755-91. [Medline]. [Full Text].

  3. Carrero P, Garrote JA, Pacheco S, et al. Report of six cases of human infection by Serratia plymuthica. J Clin Microbiol. 1995 Feb. 33(2):275-6. [Medline].

  4. Grohskopf LA, Roth VR, Feikin DR, et al. Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center. N Engl J Med. 2001 May 17. 344(20):1491-7. [Medline].

  5. Ursua PR, Unzaga MJ, Melero P, et al. Serratia rubidaea as an invasive pathogen. J Clin Microbiol. 1996 Jan. 34(1):216-7. [Medline].

  6. Julie G, Julie C, Anne G, Bernard F, Philippe V, Madeleine C, et al. Childhood delayed septic arthritis of the knee caused by Serratia fonticola. Knee. 2009 Dec. 16(6):512-4. [Medline].

  7. Elahian F, Moghimi B, Dinmohammadi F, Ghamghami M, Hamidi M, Mirzaei SA. The anticancer agent prodigiosin is not a multidrug resistance protein substrate. DNA Cell Biol. 2013 Mar. 32(3):90-7. [Medline]. [Full Text].

  8. Petersen LM, Tisa LS. Friend or foe? A review of the mechanisms that drive Serratia towards diverse lifestyles. Can J Microbiol. 2013 Sep. 59(9):627-40. [Medline].

  9. Anonymous. The miracle microbe: Serratia marcescens. [Full Text].

  10. Yu VL. Serratia marcescens: historical perspective and clinical review. N Engl J Med. 1979 Apr 19. 300(16):887-93. [Medline].

  11. Pérez-Tomás R, Viñas M. New insights on the antitumoral properties of prodiginines. Curr Med Chem. 2010. 17(21):2222-31. [Medline].

  12. Chang CC, Chen WC, Ho TF, Wu HS, Wei YH. Development of natural anti-tumor drugs by microorganisms. J Biosci Bioeng. 2011 May. 111(5):501-11. [Medline].

  13. Genes C, Baquero E, Echeverri F, Maya JD, Triana O. Mitochondrial dysfunction in Trypanosoma cruzi: the role of Serratia marcescens prodigiosin in the alternative treatment of Chagas disease. Parasit Vectors. 2011 May 6. 4:66. [Medline]. [Full Text].

  14. Remuzgo-Martínez S, Aranzamendi-Zaldunbide M, Pilares-Ortega L, Icardo JM, Acosta F, Martínez-Martínez L, et al. Interaction of macrophages with a cytotoxic Serratia liquefaciens human isolate. Microbes Infect. 2013 Jun. 15(6-7):480-90. [Medline].

  15. Gupta N, Hocevar SN, Moulton-Meissner HA, Stevens KM, McIntyre MG, Jensen B, et al. Outbreak of Serratia marcescens Bloodstream Infections in Patients Receiving Parenteral Nutrition Prepared by a Compounding Pharmacy. Clin Infect Dis. 2014 Apr 11. [Medline].

  16. Ersoz G, Uguz M, Aslan G, Horasan ES, Kaya A. Outbreak of meningitis due to Serratia marcescens after spinal anaesthesia. J Hosp Infect. 2014 Jun. 87(2):122-5. [Medline].

  17. Engel HJ, Collignon PJ, Whiting PT, Kennedy KJ. Serratia sp. bacteremia in Canberra, Australia: a population-based study over 10 years. Eur J Clin Microbiol Infect Dis. 2009 Jul. 28(7):821-4. [Medline].

  18. Samonis G, Vouloumanou EK, Christofaki M, Dimopoulou D, Maraki S, Triantafyllou E, et al. Serratia infections in a general hospital: characteristics and outcomes. Eur J Clin Microbiol Infect Dis. 2011 May. 30(5):653-60. [Medline].

  19. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010 Aug 1. 51 Suppl 1:S81-7. [Medline].

  20. Posluszny JA Jr, Conrad P, Halerz M, Shankar R, Gamelli RL. Surgical burn wound infections and their clinical implications. J Burn Care Res. 2011 Mar-Apr. 32(2):324-33. [Medline]. [Full Text].

  21. Rastogi V, Purohit P, Peters BP, et al. Pulmonary infection with serratia marcescens. Indian J Med Microbiol. 2002 Jul-Sep. 20(3):167-8. [Medline].

  22. Zarogoulidis P, Porpodis K, Konoglou M, Saroglou M, Mitrakas A, Matthaios D, et al. Serratia pneumonia presenting as hemoptysis in a patient with sarcoidosis: a case report. Int J Gen Med. 2011. 4:661-4. [Medline]. [Full Text].

  23. Wu YM, Hsu PC, Yang CC, Chang HJ, Ye JJ, Huang CT, et al. Serratia marcescens meningitis: Epidemiology, prognostic factors and treatment outcomes. J Microbiol Immunol Infect. 2012 Aug 24. [Medline].

  24. Hiremath S, Biyani M. Technique survival with Serratia peritonitis. Adv Perit Dial. 2006. 22:73-6. [Medline].

  25. Friend JC, Hilligoss DM, Marquesen M, Ulrick J, Estwick T, Turner ML, et al. Skin ulcers and disseminated abscesses are characteristic of Serratia marcescens infection in older patients with chronic granulomatous disease. J Allergy Clin Immunol. 2009 Jul. 124(1):164-6. [Medline]. [Full Text].

  26. al Hazzaa SA, Tabbara KF, Gammon JA. Pink hypopyon: a sign of Serratia marcescens endophthalmitis. Br J Ophthalmol. 1992 Dec. 76(12):764-5. [Medline].

  27. Faro J, Katz A, Berens P, Ross PJ. Premature termination of nursing secondary to Serratia marcescens breast pump contamination. Obstet Gynecol. 2011 Feb. 117(2 Pt 2):485-6. [Medline].

  28. Jones J, Crete J, Neumeier R. A case report of pink breast milk. J Obstet Gynecol Neonatal Nurs. 2014 Sep. 43(5):625-30. [Medline].

  29. Ostrowsky BE, Whitener C, Bredenberg HK, et al. Serratia marcescens bacteremia traced to an infused narcotic. N Engl J Med. 2002 May 16. 346(20):1529-37. [Medline].

  30. Sunenshine RH, Tan ET, Terashita DM, et al. A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy. Clin Infect Dis. 2007 Sep 1. 45(5):527-33. [Medline].

  31. Horcajada JP, Martinez JA, Alcon A, et al. Acquisition of multidrug-resistant Serratia marcescens by critically ill patients who consumed tap water during receipt of oral medication. Infect Control Hosp Epidemiol. 2006 Jul. 27(7):774-7. [Medline].

  32. Mills J, Drew D. Serratia marcescens endocarditis: a regional illness associated with intravenous drug abuse. Ann Intern Med. 1976 Jan. 84(1):29-35. [Medline].

  33. Pinna A, Usai D, Sechi LA, Carta A, Zanetti S. Detection of virulence factors in Serratia strains isolated from contact lens-associated corneal ulcers. Acta Ophthalmol. 2011 Jun. 89(4):382-7. [Medline].

  34. Friedman ND, Peterson NB, Sumner WT, et al. Spontaneous dermal abscesses and ulcers as a result of Serratia marcescens. J Am Acad Dermatol. 2003 Aug. 49(2 Suppl Case Reports):S193-4. [Medline].

  35. Mlynarczyk A, Mlynarczyk G, Pupek J, et al. Serratia marcescens isolated in 2005 from clinical specimens from patients with diminished immunity. Transplant Proc. 2007 Nov. 39(9):2879-82. [Medline].

  36. Bertrand X, Dowzicky MJ. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial. Clin Ther. 2012 Jan. 34(1):124-37. [Medline].

  37. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis. 2014 Apr. 78(4):443-8. [Medline].

  38. Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD, et al. The use of cefepime for treating AmpC ß-lactamase-producing Enterobacteriaceae. Clin Infect Dis. 2013 Sep. 57(6):781-8. [Medline].

  39. Curtis L. Handwashing and other environmental controls needed to prevent hospital-acquired serratia infections. J Chemother. 2009 Aug. 21(4):470. [Medline].

  40. de Vries JJ, Baas WH, van der Ploeg K, et al. Outbreak of Serratia marcescens colonization and infection traced to a healthcare worker with long-term carriage on the hands. Infect Control Hosp Epidemiol. 2006 Nov. 27(11):1153-8. [Medline].

  41. Alonso Fernandez R, Baquero Mochales F. [The genus Serratia: its biology, clinical effects and epidemiology]. Rev Clin Esp. 1994 Apr. 194(4):294-9. [Medline].

  42. Aron M, Goel R, Gupta NP, et al. Incidental detection of purulent fluid in kidney at percutaneous nephrolithotomy for branched renal calculi. J Endourol. 2005 Mar. 19(2):136-9. [Medline].

  43. Bosi C, Davin-Regli A, Charrel R, et al. Serratia marcescens nosocomial outbreak due to contamination of hexetidine solution. J Hosp Infect. 1996 Jul. 33(3):217-24. [Medline].

  44. Bruckner DA, Colonna P, Bearson BL. Nomenclature for aerobic and facultative bacteria. Clin Infect Dis. 1999 Oct. 29(4):713-23. [Medline].

  45. Buffet-Bataillon S, Rabier V, Bétrémieux P, Beuchée A, Bauer M, Pladys P, et al. Outbreak of Serratia marcescens in a neonatal intensive care unit: contaminated unmedicated liquid soap and risk factors. J Hosp Infect. 2009 May. 72(1):17-22. [Medline].

  46. Capitano B, Nicolau DP, Potoski BA, et al. Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy. 2004 Jun. 24(6):803-7. [Medline].

  47. Civen R, Vugia DJ, Alexander R, et al. Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy. Clin Infect Dis. 2006 Oct 1. 43(7):831-7. [Medline].

  48. Cohen SM, Flynn HW Jr, Miller D. Endophthalmitis caused by Serratia marcescens. Ophthalmic Surg Lasers. 1997 Mar. 28(3):195-200. [Medline].

  49. Cunha G, Leão L, Pimenta F. Bacterial contamination of random-donor platelets in a university hospital in the midwestern region of Brazil. Transfusion. 2008 Feb. 48(2):282-5. [Medline].

  50. de Boer MG, Brunsveld-Reinders AH, Salomons EM, Dijkshoorn L, Bernards AT, van den Berg PC, et al. Multifactorial origin of high incidence of Serratia marcescens in a cardio-thoracic ICU: analysis of risk factors and epidemiological characteristics. J Infect. 2008 Jun. 56(6):446-53. [Medline].

  51. Demetriou CA, Cunha BA. Serratia marcescens bacteremia after carotid endarterectomy and coronary artery bypass grafting. Heart Lung. 1999 Jul-Aug. 28(4):293-4. [Medline].

  52. Dominguez Herrera JM, Jimenez Mejias ME, et al. [Acute bacterial parotitis caused by Serratia marcescens]. Rev Clin Esp. 1996 Apr. 196(4):271-2. [Medline].

  53. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999 Aug. 29(2):239-44. [Medline].

  54. Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc. 1999 May. 74(5):519-28. [Medline].

  55. Gurevich I, Tafuro PA, Cunha BA. Serratia peritonitis in hemodialysis patients. Clinical Microbiology Newsletter. 1987. 9:55-56.

  56. Haddy RI, Mann BL, Nadkarni DD, et al. Nosocomial infection in the community hospital: severe infection due to Serratia species. J Fam Pract. 1996 Mar. 42(3):273-7. [Medline].

  57. Hejazi A, Falkiner FR. Serratia marcescens. J Med Microbiol. 1997 Nov. 46(11):903-12. [Medline].

  58. Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc. 1999 Apr. 74(4):420-34. [Medline].

  59. Heltberg O, Skov F, Gerner-Smidt P, et al. Nosocomial epidemic of Serratia marcescens septicemia ascribed to contaminated blood transfusion bags. Transfusion. 1993 Mar. 33(3):221-7. [Medline].

  60. Hertle R, Schwarz H. Serratia marcescens internalization and replication in human bladder epithelial cells. BMC Infect Dis. 2004 Jun 9. 4:16. [Medline].

  61. Hsieh S, Babl FE. Serratia marcescens cellulitis following an iguana bite. Clin Infect Dis. 1999 May. 28(5):1181-2. [Medline].

  62. Jean SS, Hsueh PR, Lee WS, Chang HT, Chou MY, Chen IS, et al. Nationwide surveillance of antimicrobial resistance among Enterobacteriaceae in intensive care units in Taiwan. Eur J Clin Microbiol Infect Dis. 2009 Feb. 28(2):215-20. [Medline].

  63. Johnson DH, Cunha BA, Klein NC. Serratia. Infect Dis Pract. 1993. 17:6-8.

  64. Johnson JS, Croall J, Power JS, et al. Fatal Serratia marcescens meningitis and myocarditis in a patient with an indwelling urinary catheter. J Clin Pathol. 1998 Oct. 51(10):789-90. [Medline].

  65. Kirschke DL, Jones TF, Craig AS, et al. Pseudomonas aeruginosa and Serratia marcescens contamination associated with a manufacturing defect in bronchoscopes. N Engl J Med. 2003 Jan 16. 348(3):214-20. [Medline].

  66. Manfredi R, Nanetti A, Ferri M, et al. Clinical and microbiological survey of Serratia marcescens infection during HIV disease. Eur J Clin Microbiol Infect Dis. 2000 Apr. 19(4):248-53. [Medline].

  67. McLeod SD, Goei SL, Taglia DP, et al. Nonulcerating bacterial keratitis associated with soft and rigid contact lens wear. Ophthalmology. 1998 Mar. 105(3):517-21. [Medline].

  68. Munoz G, Alio JL, Perez-Santonja JJ, et al. Ulcerative keratitis caused by Serratia marcescens after laser in situ keratomileusis. J Cataract Refract Surg. 2004 Feb. 30(2):507-12. [Medline].

  69. Pai HH, Chen WC, Peng CF. Cockroaches as potential vectors of nosocomial infections. Infect Control Hosp Epidemiol. 2004 Nov. 25(11):979-84. [Medline].

  70. Royo P, del Valle O, Boquete T. [Epidemiology of Serratia marcescens between 1987 and 1995 at Vall d'Hebron Hospital]. Enferm Infecc Microbiol Clin. 1997 Dec. 15(10):519-27. [Medline].

  71. Sehdev PS, Donnenberg MS. Arcanum: The 19th-century Italian pharmacist pictured here was the first to characterize what are now known to be bacteria of the genus Serratia. Clin Infect Dis. 1999 Oct. 29(4):770, 925. [Medline].

  72. Shigemura K, Arakawa S, Tanaka K, Fujisawa M. Clinical investigation of isolated bacteria from urinary tracts of hospitalized patients and their susceptibilities to antibiotics. J Infect Chemother. 2009 Feb. 15(1):18-22. [Medline].

  73. Shih HI, Lee HC, Lee NY, et al. Serratia marcescens bacteremia at a medical center in southern Taiwan: high prevalence of cefotaxime resistance. J Microbiol Immunol Infect. 2005 Oct. 38(5):350-7. [Medline].

  74. Sickbert-Bennett EE, Weber DJ, Gergen-Teague MF, et al. Comparative efficacy of hand hygiene agents in the reduction of bacteria and viruses. Am J Infect Control. 2005 Mar. 33(2):67-77. [Medline].

  75. Sokalski SJ, Jewell MA, Asmus-Shillington AC, et al. An outbreak of Serratia marcescens in 14 adult cardiac surgical patients associated with 12-lead electrocardiogram bulbs. Arch Intern Med. 1992 Apr. 152(4):841-4. [Medline].

  76. Su JR, Blossom DB, Chung W, Gullion JS, Pascoe N, Heseltine G, et al. Epidemiologic investigation of a 2007 outbreak of Serratia marcescens bloodstream infection in Texas caused by contamination of syringes prefilled with heparin and saline. Infect Control Hosp Epidemiol. 2009 Jun. 30(6):593-5. [Medline].

  77. Tanaka T, Takahashi H, Kobayashi JM, et al. A nosocomial outbreak of febrile bloodstream infection caused by heparinized-saline contaminated with Serratia marcescens, Tokyo, 2002. Jpn J Infect Dis. 2004 Oct. 57(5):189-92. [Medline].

  78. van der Vorm ER, Woldring-Zwaan C. Source, carriers, and management of a Serratia marcescens outbreak on a pulmonary unit. J Hosp Infect. 2002 Dec. 52(4):263-7. [Medline].

  79. Weinstein RA. Lessons from an epidemic, again. N Engl J Med. 2001 May 17. 344(20):1544-5. [Medline].

  80. Yannelli B, Schoch PA, Cunha BA. Serratia infections in the hospital. Clinical Microbiology Newsletter. 1987. 9:157-160.

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.